MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41467-022-33461-z

Медицинская библиотека · Nature communications · 2022

Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics.

Fraser Cameron S, Spetz Johan K E, Qin Xingping, Presser Adam, Choiniere Jonathan, Li Chendi, Yu Stacey, Blevins Frances, Hata Aaron N, Miller Jeffrey W, Bradshaw Gary A, Kalocsay Marian, Sanchorawala Vaishali, Sarosiek Shayna, Sarosiek Kristopher A

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Immunoglobulin light chain (AL) amyloidosis is an incurable hematologic disorder typically characterized by the production of amyloidogenic light chains by clonal plasma cells. These light chains misfold and aggregate in healthy tissues as amyloid fibrils, leading to life-threatening multi-organ dysfunction. Here we show that the clonal plasma cells in AL amyloidosis are highly primed to undergo apoptosis and dependent on pro-survival proteins MCL-1 and BCL-2. Notably, this MCL-1 dependency is indirectly targeted by the proteasome inhibitor bortezomib, currently the standard of care for this disease and the related plasma cell disorder multiple myeloma, due to upregulation of pro-apoptotic Noxa and its inhibitory binding to MCL-1. BCL-2 inhibitors sensitize clonal plasma cells to multiple front-line therapies including bortezomib, dexamethasone and lenalidomide. Strikingly, in mice bearing AL amyloidosis cell line xenografts, single agent treatment with the BCL-2 inhibitor ABT-199 (venetoclax) produces deeper remissions than bortezomib and triples median survival. Mass spectrometry-based proteomic analysis reveals rewiring of signaling pathways regulating apoptosis, proliferation and mitochondrial metabolism between isogenic AL amyloidosis and multiple myeloma cells that divergently alter their sensitivity to therapies. These findings provide a roadmap for the use of BH3 mimetics to exploit endogenous and induced apoptotic vulnerabilities in AL amyloidosis.

Для цитирования: Fraser Cameron S, Spetz Johan K E, Qin Xingping, Presser Adam, Choiniere Jonathan, Li Chendi, Yu Stacey, Blevins Frances, Hata Aaron N, Miller Jeffrey W, Bradshaw Gary A, Kalocsay Marian, Sanchorawala Vaishali, Sarosiek Shayna, Sarosiek Kristopher A. Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics.. Nature communications. 2022. DOI: 10.1038/s41467-022-33461-z.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.